Skip to main content
. 2023 Aug 28;19(14):4644–4656. doi: 10.7150/ijbs.84108

Figure 1.

Figure 1

Anti-Galectin-9 (αGal-9) therapy in combination with doxorubicin (Doxo) improves antitumor immunity and enhances cytotoxic T-cell activity. (a) The experimental design on a syngeneic mouse model of subcutaneous EMT6 and CT26 cancer cell lines. Mice were randomly allocated into treatment with doxo (4 mg/kg) or PBS for 7-9 days. After indicated treatment, 100 μg of αGal-9 antibody or rat IgG were injected intraperitoneally every two days four times. Values represented mean ± SD of n=5 in each group. (b) Tumor volume was measured on the indicated different treatments and time points. (c) At indicated treatment, tumor volume and Kaplan-Meier survival curves were analyzed for mice bearing EMT6 or CT26 tumors. (d-e) Immunohistochemical staining of tumor sections revealed the expressions of Ki-67 (a proliferation marker) and Gal-9 under the indicated treatment in the tumor tissue. Scale bar, 50 µm. (f) The quantification of Gal-9+; CD3+; CD8+; granzymes b+ (GB+), and CD8+ plus CD3+ cell percentage in the tumor tissue from different groups of treatment.